glp 1 behavior change Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Your Brain on GLP-1s: What

Candidates who typically benefit most from semaglutide therapy include individuals with obesity (defined medically as a body mass index of 30 or higher) or those who are overweight (with a BMI of 27 or higher) and experiencing weight-related health conditions such as elevated cholesterol, diabetes, or high blood pressure

Design, Synthesis, and in Vitro Evaluation of Novel Aminomethyl-pyridines as DPP-4 Inhibitors

Studies indicate thermoregulatory changes affect roughly 5-10% of GLP-1 users, typically during dose escalation or within the first 4-6 weeks of treatment initiation

Structured monitoring helps preserve muscle and metabolic rate during fat loss

Pre-existing mental health conditions don't automatically contraindicate GLP-1 therapy, but they warrant closer monitoring and potential mental health support

Chuansangeam M, Phadungsaksawasdi P, Park HJ, Yang YH (2025) Exploring the link between GLP-1 receptor agonists and dementia: A comprehensive review